Library/For Weight Loss/Survodutide

RUO · Not ApprovedGLP-1 / GlucagonFor Weight LossPhase 3 Ongoing+2 more

Survodutide

A dual GLP-1 and glucagon receptor agonist from Boehringer Ingelheim. We read all 60 studies. The protocol is below.

Updated 03 May 2026Read 9 minEvidence ●●●○○Citations 60

+ Add to Stack⚖ Compare

⚖ Compare side-by-side ⎙ Print companion card

Free — puts Survodutide on your decision board.

The Survodutide Report · $19

Everything you need to start: dose, sourcing, safety, our verdict.

One purchase · yours forever

Built from 60 cited studies.

Status

Research-only

Class

GLP-1 / Glucagon

Evidence

3/ 5●●●○○

FDA status

$19 ↓

Phase 2 weight loss

$19 ↓

Phase 2 MASH resolution

$19 ↓

Read this if

you saw "the next retatrutide" or "better than tirzepatide" framing on a peptide social-media account and want to know what's actually here
you have MASH or NAFLD with elevated liver enzymes and your hepatologist mentioned the phase 2 fibrosis data
you have metabolic syndrome and want to understand the GLP-1/glucagon dual mechanism
you're tracking Boehringer's SYNCHRONIZE phase 3

Skip this if

you have arrhythmia, uncontrolled hypertension, or significant cardiovascular disease — heart rate goes up like with retatrutide
you have a personal or family history of medullary thyroid carcinoma
you want an approved drug — it isn't yet
you wanted a 'better tirzepatide' — survodutide's phase 2 number (18.7%) is in the same range as tirzepatide phase 3 (22.5%), not beyond it, and there is no FDA-approved product to buy
**you're considering RUO survodutide** — pre-approval molecule, no commercial reference standard exists, so identity (is the vial actually survodutide?) is **unconfirmable** without mass spec. Identity-failures are more common than for established GLP-1s. The only way to verify is HPLC/mass-spec on the lot — most vendors don't publish one and you can't run your own.

The 4 ways you can buy Survodutide

No FDA-approved survodutide exists yet.

Compounded 503A

✓

Off-label compounding

$400–$800/mo where available

Mid–high. Few compounders carry survodutide; selling under contested legal interpretations.

RUO (research-only)

✓

Sold 'for research only'

$150–$400/mo

Pre-approval molecule, no reference standards — identity verification very hard.

Gray market

✓

Unregulated overseas import

~$65/mo

Crypto/Wise pay; pre-approval molecule, identity-failures more common than the established GLP-1s.

Click any lane for the full Sourcing breakdown. Prices and lane availability vary by molecule — this is the per-peptide snapshot, not a generic table.

First 90 days · Survodutide

What we'd actually do

Weeks 1–2

GI side effects start. Nausea is the rate-limiter. Don't titrate up if you can't tolerate the starting dose — the side-effect curve gets steeper, not flatter.

Weeks 4–8

Appetite suppression becomes the obvious effect. 1–2 lbs/week is typical. Hit a plateau? Hold the dose, don't immediately bump.

Week 12 — decide

Bloodwork: A1c, lipids, liver enzymes, fasting insulin. Visible weight change should be 5–10%. If the trajectory is flat at 12 weeks and you've titrated, this isn't your molecule.

Quit if

Pancreatitis-like pain (severe upper-abdominal, won't sit still): stop and call your doctor.
Gallbladder pain or persistent vomiting that won't resolve.
Severe muscle loss without resistance training (the 'GLP-1 face' is real — protein floor matters).
12 weeks at full dose with zero weight movement (rare, but real).

Identity

What it is.

Survodutide is Boehringer Ingelheim's entry into the next-generation weight-loss space. It's a dual agonist of the GLP-1 and glucagon receptors — different combination than tirzepatide (which is + GIP) and different from retatrutide (which is all three).

The glucagon arm is the distinctive piece. Glucagon raises blood sugar in isolation but also increases energy expenditure and drives hepatic fat oxidation. The bet is that adding glucagon agonism to produces more weight loss and meaningful liver fat reduction — which is why survodutide's most interesting trials are in MASH (metabolic dysfunction-associated steatohepatitis), the formerly-NASH liver disease.

Not FDA approved

as of mid-2026. Phase 3 trials in obesity and MASH are ongoing.

TL;DR

TL;DR. 30-second version.

The compressed verdict — what Survodutide actually is, what the human evidence shows, and the watch-for in three bullets. Locked.

Get the report · $19 ↓

Mechanism

Mechanism.

Mechanism · in the Survodutide report

How the molecule actually works — receptor profile, downstream signaling, what to expect mechanistically.

Get the report · $19 ↓

Evidence

Evidence. What we actually know in humans.

Evidence · in the Survodutide report

The trial breakdown — phase, n, primary endpoint, who funded, what hit, what didn't.

Get the report · $19 ↓

Human-Evidence Factbox

FDA status

$19 ↓

Phase 2 weight loss

$19 ↓

Phase 2 MASH resolution

$19 ↓

Receptors hit

$19 ↓

Dosing

$19 ↓

Expected approval window

$19 ↓

RUO identity verifiable?

$19 ↓

MASH use case

$19 ↓

Dose

Dose. The actual protocol.

Dose · in the Survodutide report

The specific protocol — dose, titration schedule, cycle pattern, frequency, route.

We read 60 studies to write this report.

Get the report · $19 ↓

Sourcing

Sourcing. Where the cohort actually buys.

Sourcing · in the Survodutide report

Sourcing breakdown — vendor methodology, red flags, our published test results, COA checklist.

We read 60 studies to write this report.

Get the report · $19 ↓

Safety

Safety. Side effects.

Safety · in the Survodutide report

The watch-for list — contraindications, drug interactions, monitoring labs, when to stop.

Get the report · $19 ↓

Editorial Position

Editorial position.

Editorial Position · in the Survodutide report

Our editorial position — explicit yes / no / depends, with the reasoning behind it.

Get the report · $19 ↓

Citations

Citations.

+Show all 60 citations

The Survodutide Report · $19

Everything you need to start.

Dose, sourcing, safety, our verdict. One purchase. Yours forever.

Built from 60 cited studies.

Or get every report. All reports — $99 once · Pro — $29/mo.

Compare tiers →